Payment overview · 2025
General Payments
$424.60
24 reported records · 12 companies
Healthcare provider profile · identity verified
John Michael Wisniewski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CONEMAUGH, PA · NPI 1154472579
Verified facts
What the public records show
CMS Open Payments records show John Michael Wisniewski, M.D. received $424.60 in general payments during 2025 across 24 reported records.
Lilly USA, LLC accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.16 | 17.5% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $73.44 | 17.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.35 | 16.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.25 | 13.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.24 | 8.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.87 | 4.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.69 | 3.9% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $16.65 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.11 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.71 | 3.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.17 | 3.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.96 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.60 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $73.44 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.35 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.25 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 333 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
333 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1046 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 727 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 119 |
| Potassium Chloride | Potassium Chloride | 571 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 545 | 117 |
| Metoprolol Tartrate | Metoprolol Tartrate | 461 | 70 |
| Metformin Hcl | Metformin Hcl | 383 | 90 |
| Furosemide | Furosemide | 346 | 73 |
| Eliquis | Apixaban | 333 | 51 |
| Sertraline Hcl | Sertraline Hcl | 321 | 64 |
| Donepezil Hcl | Donepezil Hcl | 315 | 41 |
| Losartan Potassium | Losartan Potassium | 315 | 75 |
| Lisinopril | Lisinopril | 313 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 61 |
| Gabapentin | Gabapentin | 261 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 245 | 50 |
| Tradjenta | Linagliptin | 244 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 239 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 231 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 53 |
| Simvastatin | Simvastatin | 207 | 41 |
| Omeprazole | Omeprazole | 194 | 36 |
| Trazodone Hcl | Trazodone Hcl | 194 | 32 |
| Memantine Hcl | Memantine Hcl | 192 | 20 |
| Warfarin Sodium | Warfarin Sodium | 174 | 15 |
| Jardiance | Empagliflozin | 167 | 25 |
| Famotidine | Famotidine | 163 | 28 |
| Allopurinol | Allopurinol | 148 | 26 |
| Mirtazapine | Mirtazapine | 145 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | 21 |
| Lorazepam | Lorazepam | 133 | 38 |
| Xarelto | Rivaroxaban | 128 | 14 |
| Carvedilol | Carvedilol | 125 | 25 |
| Montelukast Sodium | Montelukast Sodium | 116 | 21 |
| Amantadine | Amantadine Hcl | 112 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 104 | 12 |
| Digoxin | Digoxin | 100 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 23 |
| Alprazolam | Alprazolam | 87 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 22 |
| Levetiracetam | Levetiracetam | 86 | 12 |
| Meloxicam | Meloxicam | 79 | 15 |
| Trulicity | Dulaglutide | 75 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 73 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 72 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Atenolol | Atenolol | 70 | 16 |
| Alendronate Sodium | Alendronate Sodium | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Prednisone | Prednisone | 65 | 39 |
| Spironolactone | Spironolactone | 65 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 16 |
| Synthroid | Levothyroxine Sodium | 59 | 18 |
| Tramadol Hcl | Tramadol Hcl | 59 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 12 |
| Glipizide | Glipizide | 52 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 14 |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 23 |
| Latanoprost | Latanoprost | 44 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 25 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Jantoven | Warfarin Sodium | 34 | suppressed |
| Calcitriol | Calcitriol | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 14 |
| Perphenazine | Perphenazine | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 21 |
| Dutasteride | Dutasteride | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 21 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Entacapone | Entacapone | 20 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Trimethoprim | Trimethoprim | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.60 · 24 records | Lilly USA, LLC | AIRSUPRA, CAPLYTA, ELIQUIS, Flexitouch Plus, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, Nimbl, Ohtuvayre, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error